VivoSeq
Neurology

Cerebral Cavernous Malformation

5

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Cerebral Cavernous Malformation is an early-stage landscape with 5 programs across 5 companies. The most active players are Johnson & Johnson, Recursion Pharmaceuticals Inc., Eli Lilly. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

67/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1R

Recursion Pharmaceuticals Inc.

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedMario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 83% of 6 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Terminated1 · 25%
Not yet recruiting1 · 25%

Clinical Trials

Trial Activity

Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
Terminated·UUniversity of New Mexico·Phase 1·NCT01764451·12 enrolled
Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation
Completed·Mario Negri Institute for Pharmacological Research logoMario Negri Institute for Pharmacological Research·Phase 2·NCT03589014·71 enrolled
Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study
Not yet recruiting·—·Phase 1·NCT07026604·10 enrolled
A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994
Completed·RRecursion Pharmaceuticals Inc.·Phase 2·NCT05085561·62 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)